Recombinant human hair keratin proteins for halting bleeding
Source abstract
Abstract
Keratins derived from human hair have been widely used for tissue engineering. However, some drawbacks relative to the traditional keratins extracts have been found: (a): difficultly controlling the amino acid composition; (b): batch to batch inconsistent quality; and (c): producing complex keratin and keratin-associated proteins (KAPs), which problems have made some studies concerning human hair keratins stagnant, especially in the mechanism studies related to hemostasis of keratins. Herein, a type-I human hair keratin of K37 and a type-II human hair keratin of K81 were heterologously expressed and firstly used for haemostatic application. SDS-PAGE analysis shows that the recombinant keratins had higher purity compared to the extracted keratins. The circular dichroism (CD) spectra of K37 and K81 suggested that the secondary structures were rich in α-helix. In addition, the recombinant keratin proteins could enhance fibrin colt formation at the site of injury and decrease the bleeding time and blood loss in liver puncture and femoral artery injury rat models. This study provides a new strategy for future works involving design and mechanism studies of keratin biomaterials.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Dyeing and Modifying Textile Fibers · Hair Growth and Disorders · Skin Protection and Aging
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China;
Collaborative Innovation Center for Brain Science, Chongqing University, Chongqing, China
Funding
National Natural Science Foundation of China · National Basic Research Program of China
References (24)
Show source-provided references
1. 10.1186/s12951-018-0353-210.1186/s12951-018-0353-2 ↗
2. 10.1080/21691401.2017.134977810.1080/21691401.2017.1349778 ↗
3. 10.3109/21691401.2015.103699910.3109/21691401.2015.1036999 ↗
4. 10.1021/acsami.5b0085410.1021/acsami.5b00854 ↗
5. 10.1016/j.msec.2016.03.00710.1016/j.msec.2016.03.007 ↗
6. 10.1016/j.biomaterials.2012.12.02210.1016/j.biomaterials.2012.12.022 ↗
7. 10.1016/j.biomaterials.2007.08.02310.1016/j.biomaterials.2007.08.023 ↗
8. 10.1016/j.biomaterials.2012.12.00810.1016/j.biomaterials.2012.12.008 ↗
9. 10.3390/ma302099910.3390/ma3020999 ↗
10. 10.1042/bj167048910.1042/bj1670489 ↗
11. 10.1016/j.msec.2016.11.07110.1016/j.msec.2016.11.071 ↗
12. 10.1016/j.colsurfb.2016.10.03810.1016/j.colsurfb.2016.10.038 ↗
13. 10.1002/bip.2303710.1002/bip.23037 ↗
14. 10.1016/j.msec.2016.07.03510.1016/j.msec.2016.07.035 ↗
15. 10.1074/mcp.M500278-MCP20010.1074/mcp.M500278-MCP200 ↗
16. 10.1007/s00418-008-0435-610.1007/s00418-008-0435-6 ↗
17. 10.1038/sj.jid.570053210.1038/sj.jid.5700532 ↗
18. 10.1083/jcb.111.1.15310.1083/jcb.111.1.153 ↗
19. Zhang M · Artif Cells Nanomed Biotechnol · 2017 · 19 · 1
20. 10.1016/j.actbio.2011.08.02010.1016/j.actbio.2011.08.020 ↗
21. 10.1038/srep0959410.1038/srep09594 ↗
22. 10.1039/C4GC00213J10.1039/C4GC00213J ↗
23. 10.1016/S0040-6031(99)00055-610.1016/S0040-6031(99)00055-6 ↗
24. 10.1016/j.biomaterials.2012.09.06010.1016/j.biomaterials.2012.09.060 ↗